Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. ACHC
ACHC logo

ACHC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
25.200
Open
24.980
VWAP
24.87
Vol
3.01M
Mkt Cap
2.32B
Low
24.270
Amount
74.83M
EV/EBITDA(TTM)
8.40
Total Shares
92.21M
EV
4.85B
EV/OCF(TTM)
36.76
P/S(TTM)
0.68
Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services across the United States. It provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics. Its acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. Its specialty treatment facilities include residential recovery facilities and eating disorder facilities. Its comprehensive treatment centers specialize in providing medication-assisted treatment in an outpatient setting. Its residential treatment centers treat patients with behavioral disorders in a non-hospital setting. The facilities balance therapy activities with social, academic and other activities. It operates a network of 262 behavioral healthcare facilities with over 11,850 beds in 39 states and Puerto Rico.
Show More

Events Timeline

(ET)
2026-02-25
16:40:00
Nasdaq Rises 1.26% as Investors Await Nvidia Earnings
select
2026-02-25
12:10:00
Nasdaq Rises 1.09% as Nvidia Earnings Report Draws Attention
select
2026-02-25
07:40:00
Company Sees FY26 Revenue of $3.37B to $3.45B
select

News

PRnewswire
8.5
03-05PRnewswire
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
  • Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
  • Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
  • Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
  • Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
Newsfilter
8.5
03-05Newsfilter
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
  • Market Growth Potential: The global market for generalized anxiety disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a 9% annual growth rate driven by increasing awareness of mental health and demand for innovative solutions.
  • Therapeutic Innovation: Helus Pharma's HLP004 demonstrated significant efficacy in a Phase 2 clinical trial for moderate-to-severe GAD patients, achieving an average reduction of 10.4 points in the Hamilton Anxiety Rating Scale (p<0.0001) within six weeks, offering new hope for patients who have not responded to existing treatments.
  • Positive Patient Response: At six months, 67% of participants showed treatment response and 39% achieved remission, indicating that HLP004 provides durable effects and could potentially transform the treatment landscape for GAD.
  • Optimistic Industry Outlook: The rise of digital mental health tools and telehealth has significantly improved treatment accessibility, and investments by Helus Pharma and other companies in mental health solutions are expected to drive continued market growth to meet the increasing patient demand.
Fool
6.5
03-03Fool
Canyon Capital Advisors Exits Acadia Healthcare Position Completely
  • Complete Exit: Canyon Capital Advisors fully exited its position in Acadia Healthcare by selling 521,774 shares in Q4 2026, resulting in a decrease of approximately $12.92 million in position value, indicating a pessimistic outlook on the company's future prospects.
  • Poor Stock Performance: As of Tuesday, Acadia Healthcare's shares were priced at $22.74, down 22% over the past year, significantly underperforming the S&P 500, which rose about 16%, highlighting the company's lack of competitiveness in the market.
  • Complex Financial Situation: Despite a 6.1% year-over-year revenue increase to $821.5 million in Q4, the company faced a $996.2 million goodwill impairment, leading to an adjusted EBITDA drop to $608.9 million, indicating operational pressures with a net leverage of 4.0x limiting financial flexibility.
  • Uncertain Market Outlook: Canyon's exit suggests a preference for clearer asset-backed recovery plays over healthcare turnaround risks, prompting long-term investors to monitor occupancy trends and liability reserve stability to gauge future market sentiment shifts.
NASDAQ.COM
2.0
03-03NASDAQ.COM
Canyon Capital Fully Exits Acadia Healthcare Position
  • Shareholding Change: Canyon Capital sold 521,774 shares of Acadia Healthcare in Q4, resulting in a decrease of approximately $12.92 million in position value, indicating a significant loss of confidence in the company.
  • Financial Performance: Although Acadia Healthcare reported a 6.1% revenue increase to $821.5 million in Q4, the adjusted EBITDA fell to $608.9 million due to a $996.2 million goodwill impairment, highlighting the financial pressures the company faces.
  • Market Environment: Acadia Healthcare's stock has declined about 20% over the past year, with a staggering drop of up to 60% in recent months, reflecting the company's vulnerability amid broader financial pressures, warranting caution from investors.
  • Investment Strategy Shift: Canyon Capital's exit suggests a preference for asset-backed recovery plays over healthcare turnaround risks, necessitating close monitoring of Acadia's occupancy trends and liability reserve stability moving forward.
Yahoo Finance
6.0
02-26Yahoo Finance
Acadia Healthcare Receives Overweight Rating
  • Rating Analysis: Acadia Healthcare (ACHC) has received an overweight rating, indicating analysts' optimistic expectations for its future performance, which may attract more investor attention.
  • Price Target: The average price target set by analysts is $22, suggesting there is room for stock price appreciation, which could yield substantial returns for investors if achieved.
  • Market Confidence: The overweight rating reflects market confidence in Acadia Healthcare's continued growth potential within the healthcare sector, potentially driving its stock price higher.
  • Investment Appeal: With analysts' positive evaluations of Acadia Healthcare, it is expected to attract more institutional investors, further enhancing its market performance.
seekingalpha
9.5
02-25seekingalpha
Acadia Healthcare Q4 2025 Earnings Call Insights
  • Leadership Transition: CEO Debra Osteen emphasized a renewed focus on stability and execution, planning to enhance company performance by reinforcing operational discipline and supporting field teams, aiming to lay a foundation for future success.
  • Financial Performance Review: Q4 2025 revenue reached $821.5 million, a 6.1% year-over-year increase, with adjusted EBITDA at $99.8 million, reflecting a 4.4% growth in same-facility revenue driven by a 1.3% increase in revenue per patient day and a 3.1% rise in patient days.
  • Future Outlook: The company expects 2026 revenue between $3.37 billion and $3.45 billion, with adjusted EBITDA projected at $575 million to $610 million, reflecting expectations for same-facility growth and anticipated start-up losses from new facilities.
  • Capital Expenditure Management: Total capital expenditures for 2025 amounted to $572 million, below guidance, with management stressing that each project must demonstrate clear market fundamentals and patient needs to ensure effective capital utilization.
Wall Street analysts forecast ACHC stock price to rise
11 Analyst Rating
Wall Street analysts forecast ACHC stock price to rise
5 Buy
5 Hold
1 Sell
Moderate Buy
Current: 0.000
sliders
Low
13.00
Averages
18.10
High
25.00
Current: 0.000
sliders
Low
13.00
Averages
18.10
High
25.00
Barclays
Andrew Mok
Equal Weight
maintain
$14 -> $20
AI Analysis
2026-03-02
Reason
Barclays
Andrew Mok
Price Target
$14 -> $20
AI Analysis
2026-03-02
maintain
Equal Weight
Reason
Barclays analyst Andrew Mok raised the firm's price target on Acadia Healthcare to $20 from $14 and keeps an Equal Weight rating on the shares.
UBS
Buy
maintain
$24 -> $27
2026-02-26
Reason
UBS
Price Target
$24 -> $27
2026-02-26
maintain
Buy
Reason
UBS raised the firm's price target on Acadia Healthcare to $27 from $24 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ACHC
Unlock Now

Valuation Metrics

The current forward P/E ratio for Acadia Healthcare Company Inc (ACHC.O) is 8.27, compared to its 5-year average forward P/E of 19.03. For a more detailed relative valuation and DCF analysis to assess Acadia Healthcare Company Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
19.03
Current PE
8.27
Overvalued PE
24.45
Undervalued PE
13.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
11.05
Current EV/EBITDA
6.24
Overvalued EV/EBITDA
13.69
Undervalued EV/EBITDA
8.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.92
Current PS
0.39
Overvalued PS
2.62
Undervalued PS
1.22

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

best stock picks for swing trade this week
Intellectia · 928 candidates
Region: USPrice: $5.00 - $150.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
CAKE logo
CAKE
Cheesecake Factory Inc
3.14B
ACHC logo
ACHC
Acadia Healthcare Company Inc
2.16B
AM logo
AM
Antero Midstream Corp
10.84B
KDP logo
KDP
Keurig Dr Pepper Inc
40.72B
SAH logo
SAH
Sonic Automotive Inc
2.06B
FAF logo
FAF
First American Financial Corp
7.16B
What the best trade I can take now
Intellectia · 85 candidates
Region: USPrice: $15.00 - $120.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Week Rise Prob: >= 75Monthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
SON logo
SON
Sonoco Products Co
5.57B
WBS logo
WBS
Webster Financial Corp
11.63B
CMCL logo
CMCL
Caledonia Mining Corporation PLC
612.73M
AVTX logo
AVTX
Avalo Therapeutics Inc
323.97M
CAKE logo
CAKE
Cheesecake Factory Inc
3.23B
ALNT logo
ALNT
Allient Inc
1.12B
what is a good short term buy today?
Intellectia · 64 candidates
Market Cap: >= 1000.00MRsi Category: moderateRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $5.00
Ticker
Name
Market Cap$
top bottom
ACHC logo
ACHC
Acadia Healthcare Company Inc
1.32B
PLAB logo
PLAB
Photronics Inc
2.14B
EDN logo
EDN
Empresa Distribuidora y Comercializadora Norte SA
1.34B
DAWN logo
DAWN
Day One Biopharmaceuticals Inc
1.24B
ALM logo
ALM
Almonty Industries Inc
2.60B
MYRG logo
MYRG
MYR Group Inc
3.99B
small cap stocks for day trading
Intellectia · 130 candidates
Market Cap: <= 2.00BRelative Vol: >= 1.50Weekly Average Turnover: >= 1,000,000Week Price Change Pct: >= $5.00
Ticker
Name
Market Cap$
top bottom
CRVS logo
CRVS
Corvus Pharmaceuticals Inc
1.65B
RCAT logo
RCAT
Red Cat Holdings Inc
1.86B
RR logo
RR
Richtech Robotics Inc
937.82M
BNAI logo
BNAI
Brand Engagement Network Inc
46.54M
PAVM logo
PAVM
PAVmed Inc
11.92M
AMPX logo
AMPX
Amprius Technologies Inc
1.47B
que debería invertir a corto plazo
Intellectia · 64 candidates
Market Cap: >= 1000.00MRsi Category: moderateRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $5.00
Ticker
Name
Market Cap$
top bottom
ACHC logo
ACHC
Acadia Healthcare Company Inc
1.32B
PLAB logo
PLAB
Photronics Inc
2.14B
EDN logo
EDN
Empresa Distribuidora y Comercializadora Norte SA
1.34B
DAWN logo
DAWN
Day One Biopharmaceuticals Inc
1.24B
ALM logo
ALM
Almonty Industries Inc
2.60B
MYRG logo
MYRG
MYR Group Inc
3.99B
give me best 1 stock
Intellectia · 615 candidates
Net Margin: >= 0.00Relative Vol: >= 1.50
Ticker
Name
Market Cap$
top bottom
SLGB logo
SLGB
Smart Logistics Global Ltd
75.44M
RFIL logo
RFIL
RF Industries Ltd
128.46M
TII logo
TII
Titan Mining Corp
470.91M
SJ logo
SJ
Scienjoy Holding Corp
49.11M
RAY logo
RAY
Raytech Holding Ltd
12.70M
MRAM logo
MRAM
Everspin Technologies Inc
367.53M
good. short term buys
Intellectia · 16 candidates
Relative Vol: >= 1.20Weekly Average Turnover: >= 1,000,000Rsi 14: 40 - 70Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $20.00
Ticker
Name
Market Cap$
top bottom
ACHC logo
ACHC
Acadia Healthcare Company Inc
1.32B
DBVT logo
DBVT
Dbv Technologies SA
1.18B
FCEL logo
FCEL
Fuelcell Energy Inc
446.34M
NFE logo
NFE
New Fortress Energy Inc
441.06M
AVR logo
AVR
Anteris Technologies Global Corp
249.66M
TRUE logo
TRUE
TrueCar Inc
225.91M
Best stock for next 7 dayz
Intellectia · 239 candidates
Market Cap: >= 1000.00MRelative Vol: >= 1.50Weekly Average Turnover: >= 1,000,000Rsi 14: 30 - 70Week Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
ACHC logo
ACHC
Acadia Healthcare Company Inc
1.32B
PLAB logo
PLAB
Photronics Inc
2.14B
EDN logo
EDN
Empresa Distribuidora y Comercializadora Norte SA
1.34B
DAWN logo
DAWN
Day One Biopharmaceuticals Inc
1.24B
ALM logo
ALM
Almonty Industries Inc
2.60B
MYRG logo
MYRG
MYR Group Inc
3.99B
best medical 3 stocks to buy under $20
Intellectia · 22 candidates
Market Cap: >= 500.00MPrice: <= $20.00Beta: LowRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
TAK logo
TAK
Takeda Pharmaceutical Co Ltd
51.17B
HLN logo
HLN
Haleon PLC
45.60B
KVUE logo
KVUE
Kenvue Inc
33.30B
VTRS logo
VTRS
Viatris Inc
15.03B
RDY logo
RDY
Dr Reddy's Laboratories Ltd
11.06B
BAX logo
BAX
Baxter International Inc
10.13B

Whales Holding ACHC

H
Hawk Ridge Capital Management LP
Holding
ACHC
+6.69%
3M Return
I
Invenomic Capital Management LP
Holding
ACHC
+5.00%
3M Return
J
Jefferies Financial Group Inc.
Holding
ACHC
+2.68%
3M Return
G
Greenlight Capital, Inc.
Holding
ACHC
+1.58%
3M Return
A
Abrams Bison Investments, L.L.C.
Holding
ACHC
+0.19%
3M Return
D
Deerfield Management Company, L.P.
Holding
ACHC
+0.18%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Acadia Healthcare Company Inc (ACHC) stock price today?

The current price of ACHC is 25.14 USD — it has increased 1.74

What is Acadia Healthcare Company Inc (ACHC)'s business?

Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services across the United States. It provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics. Its acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. Its specialty treatment facilities include residential recovery facilities and eating disorder facilities. Its comprehensive treatment centers specialize in providing medication-assisted treatment in an outpatient setting. Its residential treatment centers treat patients with behavioral disorders in a non-hospital setting. The facilities balance therapy activities with social, academic and other activities. It operates a network of 262 behavioral healthcare facilities with over 11,850 beds in 39 states and Puerto Rico.

What is the price predicton of ACHC Stock?

Wall Street analysts forecast ACHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACHC is18.10 USD with a low forecast of 13.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Acadia Healthcare Company Inc (ACHC)'s revenue for the last quarter?

Acadia Healthcare Company Inc revenue for the last quarter amounts to 821.46M USD, increased 6.10

What is Acadia Healthcare Company Inc (ACHC)'s earnings per share (EPS) for the last quarter?

Acadia Healthcare Company Inc. EPS for the last quarter amounts to -13.02 USD, decreased -3820.00

How many employees does Acadia Healthcare Company Inc (ACHC). have?

Acadia Healthcare Company Inc (ACHC) has 19000 emplpoyees as of March 11 2026.

What is Acadia Healthcare Company Inc (ACHC) market cap?

Today ACHC has the market capitalization of 2.32B USD.